---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-072529"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:23:21.181224+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharmaceuticals announces 1-for-20 reverse stock split effective August 4, 2025 to regain Nasdaq compliance

## Summary
- Reverse split ratio 1-for-20; effective 4:01 p.m. ET on August 4, 2025.
- Post-split trading begins August 5, 2025 under ticker ACXP; new CUSIP 00510M 203.
- Outstanding shares reduced from ~30.8M to ~1.5M; authorized shares unchanged.
- Fractional shares paid in cash based on August 1, 2025 closing price.
- Split approved by stockholders at July 17, 2025 annual meeting; intended to regain Nasdaq minimum bid price compliance.

## SEC filing metadata
- accession: 0001104659-25-072529
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465925072529/0001104659-25-072529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465925072529/tm2521773d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-072529
- JSON: https://secwatch.observer/filing/0001104659-25-072529.json
- Plain text: https://secwatch.observer/filing/0001104659-25-072529.txt

## Key facts
- Governance Changes
  Acurx Pharmaceuticals, Inc.: Filing of certificate of amendment to effect a 1-for-20 reverse stock split of common stock, effective August 4, 2025 at 4:01 p.m. Eastern Time (effective 2025-08-04).
  - Change: charter amendment
  - Effective: 2025-08-04
  source text: On July 31, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its certificate of incorporation to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-20 (the “Reverse Stock Split”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465925072529/0001104659-25-072529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.